PADCEV
30mgPADCEV30mg
PADCEV (Enfortumab Vedotin-ejfv) 30mg is a first-in-class Nectin-4-directed antibody-drug conjugate (ADC) for locally advanced or metastatic urothelial carcinoma (bladder cancer).
Key Benefits
- First-in-class Nectin-4-directed ADC for bladder cancer
- Nearly doubled overall survival vs chemo in EV-302 (31.5 vs 16.1 months)
- FDA-approved first-line with Keytruda — replaces chemotherapy
- 67.7% overall response rate including 29.1% complete responses
- Targets >95% of urothelial carcinomas via Nectin-4
- Eliminates need for cisplatin-based nephrotoxic chemotherapy
Contact Us for Pricing
Get competitive wholesale pricing for PADCEV 30mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How PADCEV Works
Padcev is a Nectin-4-directed ADC. The anti-Nectin-4 antibody binds to cancer cells, the complex is internalized, the vc linker is cleaved by intracellular proteases, and MMAE is released to disrupt microtubules, causing cell cycle arrest and apoptosis.
About PADCEV 30mg
PADCEV (Enfortumab Vedotin-ejfv) 30mg by Astellas/Seagen (Pfizer) is the first Nectin-4-directed ADC that has revolutionized bladder cancer treatment. In 2023, Padcev gained landmark first-line FDA approval in combination with pembrolizumab (Keytruda), replacing chemotherapy as the new standard of care based on the practice-changing EV-302/KEYNOTE-A39 trial. The EV-302 trial demonstrated that Padcev + Keytruda nearly doubled overall survival compared to gemcitabine/platinum chemotherapy (31.5 vs 16.1 months, HR=0.47), representing the biggest paradigm shift in urothelial cancer treatment in decades. Padcev targets Nectin-4, a cell adhesion molecule expressed on >95% of urothelial carcinomas. The ADC is internalized, releases MMAE cytotoxic payload, and destroys cancer cells from within. This targeted mechanism provides superior efficacy with a manageable safety profile. As a licensed pharmaceutical supplier, we provide authentic Astellas Padcev with validated cold chain handling, certificate of authenticity, and competitive wholesale pricing for hospitals and oncology centers worldwide.
Common Uses
- Locally advanced or metastatic urothelial carcinoma (bladder cancer)
- First-line treatment in combination with pembrolizumab (Keytruda)
- Previously treated urothelial carcinoma after platinum and checkpoint inhibitor
- Urothelial cancer of renal pelvis, ureter, urethra
Dosage Information
1.25 mg/kg (max 125 mg) IV over 30 min. Monotherapy: Days 1, 8, 15 of 28-day cycle. With pembrolizumab: Days 1, 8 of 21-day cycle. Continue until progression or unacceptable toxicity.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. Reconstitute with 3.3 mL SWFI. After dilution, stable up to 24 hours at 2-8°C or 8 hours at room temperature.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About PADCEV
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
